This prospective observational study aims to evaluate serum Neuregulin-4 (NRG4) concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus (T2DM) and to investigate their association with obesity status, insulin resistance, and different antidiabetic treatment regimens. Participants will be categorized into five predefined groups according to obesity status and treatment regimen, including SGLT2 inhibitor users, non-SGLT2 oral antidiabetic therapy users, SGLT2 combination therapy users, newly diagnosed treatment-naïve patients, and healthy controls. Clinical, anthropometric, and laboratory parameters including fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR), body mass index, waist circumference, waist-to-hip ratio, and serum NRG4 concentrations will be evaluated. The study aims to determine whether NRG4 may serve as a novel biomarker reflecting metabolic status and treatment response in patients with T2DM.
Inclusion Criteria:
Exclusion Criteria:
ganataca@yahoo.com+905059284244
Type 2 Diabetes Mellitus patients receiving only SGLT2 inhibitor treatment will be included in this group. Serum NRG4 levels and metabolic parameters will be evaluated.
Type 2 Diabetes Mellitus patients receiving metformin with or without insulin therapy, but not receiving SGLT2 inhibitors, will be included in this group.
Type 2 Diabetes Mellitus patients receiving metformin with or without insulin together with SGLT2 inhibitor therapy will be included in this group.
Newly diagnosed treatment-naive Type 2 Diabetes Mellitus patients who have not received any antidiabetic therapy will be included in this group.
Age-matched participants without Diabetes Mellitus diagnosis will be included as healthy controls for comparison of serum NRG4 levels and metabolic parameters.
Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus
Molecular and Clinical Profile of Diabetes Mellitus and Its Complications
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention
A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity
Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)